An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.

Yoshiyuki MiyazawaYoshitaka SekineNobuaki ShimizuYutaka TakezawaToshiyuki NakamuraTakeshi MiyaoHiroshi NakayamaSota KuriharaTakahiro SyutoMasashi NomuraHidekazu KoikeHiroshi MatsuiYasuhiro ShibataKazuhiro Suzuki

Published in: The Prostate (2019)

Our study has demonstrated that PSA dynamics after ENZ administration may be a useful prognostic factor for mCRPC patients.

Keyphrases

prognostic factors
prostate cancer
patients undergoing
radical prostatectomy
end stage renal disease
newly diagnosed
ejection fraction
combination therapy
aqueous solution